https://sofinnovapartners.com/news/noema-pharma-noe-105-gemlapodect-phase-2a-study-tourette-syndrome-met
Noema Pharma's gemlapodect meets Phase 2a endpoints in Tourette — Sofinnova Partners
Oct 17, 2024 - Noema Pharma's gemlapodect met primary and key secondary endpoints in the ALLEVIA-1 Phase 2a Tourette study, with no serious adverse events.
noemapharmagemlapodectmeetsphase